Skip to main content
SpringerLink
Log in

Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Accurate prediction of human pharmacokinetics for drugs remains challenging, especially for non-cytochrome P450 (P450) substrates. Hepatocytes might be suitable for predicting hepatic intrinsic clearance (CLint) of new chemical entities, because they can be applied to various compounds regardless of the metabolic enzymes. However, it was reported that hepatic CLint is underestimated in hepatocytes. The purpose of the present study was to confirm the predictability of human hepatic clearance for P450 and non-P450 substrates in hepatocytes and the utility of animal scaling factors for the prediction using hepatocytes. CLint values for 30 substrates of P450, UDP-glucuronosyltransferase, flavin-containing monooxygenase, esterases, reductases, and aldehyde oxidase in human microsomes, human S9 and human, rat, and monkey hepatocytes were estimated. Hepatocytes were incubated in serum of each species. Furthermore, CLint values in human hepatocytes were corrected with empirical, monkey, and rat scaling factors. CLint values in hepatocytes for most compounds were underestimated compared to observed values regardless of the metabolic enzyme, and the predictability was improved by using the scaling factors. The prediction using human hepatocytes corrected with monkey scaling factor showed the highest predictability for both P450 and non-P450 substrates among the predictions using liver microsomes, liver S9, and hepatocytes with or without scaling factors. CLint values by this method for 80% and 90% of all compounds were within 2- and 3-fold of observed values, respectively. This method is accurate and useful for estimating new chemical entities, with no need to care about cofactors, localization of metabolic enzymes, or protein binding in plasma and incubation mixture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Obach RS. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Dev 2013. 2001;4:36–44.

    CAS  Google Scholar 

  2. Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000;84:213–20.

    CAS  PubMed  Google Scholar 

  3. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4:825–33.

    CAS  PubMed  Google Scholar 

  4. Mordenti J. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci. 1985;74:1097–9.

    CAS  PubMed  Google Scholar 

  5. Ings RM. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica. 1990;20:1201–31.

    CAS  PubMed  Google Scholar 

  6. Lavé T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet. 1999;36:211–31.

    PubMed  Google Scholar 

  7. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47:1469–79.

    CAS  PubMed  Google Scholar 

  8. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 1997;73:147–71.

    CAS  PubMed  Google Scholar 

  9. Hallifax D, Houston JB. Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr Drug Metab. 2009;10:307–21.

    CAS  PubMed  Google Scholar 

  10. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–5.

    CAS  PubMed  Google Scholar 

  11. Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos. 2003;31:606–11.

    CAS  PubMed  Google Scholar 

  12. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 2009;11:262–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Riccardi K, Cawley S, Yates PD, Chang C, Funk C, Niosi M, et al. Plasma protein binding of challenging compounds. J Pharm Sci. 2015;104:2627–36.

    CAS  PubMed  Google Scholar 

  14. Shibata Y, Takahashi H, Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos. 2000;28:1518–23.

    CAS  PubMed  Google Scholar 

  15. Shibata Y, Takahashi H, Chiba M, Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos. 2002;30:892–6.

    CAS  PubMed  Google Scholar 

  16. Shibata Y, Kuze J, Chiba M. Utility of cryopreserved hepatocytes suspended in serum to predict hepatic clearance in dogs and monkeys. Drug Metab Pharmacokinet. 2014;29:168–76.

    CAS  PubMed  Google Scholar 

  17. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos. 2001;29:1316–24.

    CAS  PubMed  Google Scholar 

  18. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos. 2003;31:580–8.

    CAS  PubMed  Google Scholar 

  19. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos. 2000;28:560–6.

    CAS  PubMed  Google Scholar 

  20. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos. 2009;37:82–9.

    CAS  PubMed  Google Scholar 

  21. Zhang Y, Yao L, Lin J, Gao H, Wilson TC, Giragossian C. Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci. 2010;99:3620–7.

    CAS  PubMed  Google Scholar 

  22. Langmuir I. The adsorption of gases on plane surfaces of glass, mica and platinum. J Am Chem Soc. 1918;40:1361–403.

    CAS  Google Scholar 

  23. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009;49:513–33.

    CAS  PubMed  Google Scholar 

  24. Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab. 2008;9:940–51.

    CAS  PubMed  Google Scholar 

  25. Roberts MS, Rowland M. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics; analysis with a dispersion model. J Pharm Pharmacol. 1986;38:177–81.

    CAS  PubMed  Google Scholar 

  26. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997;283:46–58.

    CAS  PubMed  Google Scholar 

  27. Wood FL, Houston JB, Hallifax D. Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes/microsomes and implications for experimental methodology. Drug Metab Dispos. 2017;45:1178–88.

    CAS  PubMed  Google Scholar 

  28. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97–132.

    CAS  PubMed  Google Scholar 

  29. Gill KL, Houston JB, Galetin A. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012;40:825–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci. 2001;61:49–53.

    CAS  PubMed  Google Scholar 

  31. Mano Y, Usui T, Kamimura H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007;35:2040–4.

    CAS  PubMed  Google Scholar 

  32. Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, et al. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011;21:523–30.

    CAS  PubMed  Google Scholar 

  33. Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact. 1997;106:29–45.

    CAS  PubMed  Google Scholar 

  34. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos. 1997;25:524–7.

    CAS  PubMed  Google Scholar 

  35. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004;32:1201–8.

    CAS  PubMed  Google Scholar 

  36. Fukami T, Yokoi T. The emerging role of human esterases. Drug Metab Pharmacokinet. 2012;27:466–77.

    CAS  PubMed  Google Scholar 

  37. Franssen EJF, Greuter HNJM, Touw DJ, Luurtsema G, Windhorst AD, Lammertsma AA. Plasma pharmacokinetics of [11C]-flumazenil and its major metabolite [11C]-flumazenil ‘acid’. Br J Clin Pharmacol. 2002;53:554Pb.

    PubMed Central  Google Scholar 

  38. Lukkari E, Taavitsainen P, Juhakoski A, Pelkonen O. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol Toxicol. 1998;82:161–6.

    CAS  PubMed  Google Scholar 

  39. Sato Y, Miyashita A, Iwatsubo T, Usui T. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos. 2012;40:902–6.

    CAS  PubMed  Google Scholar 

  40. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52:225–41.

    CAS  PubMed  Google Scholar 

  41. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 1998;38:257–88.

    CAS  PubMed  Google Scholar 

  42. Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem Pharmacol. 1995;49:421–40.

    CAS  PubMed  Google Scholar 

  43. Oppermann UC, Maser E. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology. 2000;144:71–81.

    CAS  PubMed  Google Scholar 

  44. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol. 1996;24:48–57.

    CAS  PubMed  Google Scholar 

  45. Rosemond MJ, Walsh JS. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev. 2004;36:335–61.

    CAS  PubMed  Google Scholar 

  46. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435–56.

    CAS  PubMed  Google Scholar 

  47. Dawson M, Braithwaite PA, Roberts MS, Watson TR. The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. Br J Clin Pharmacol. 1985;19:79–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Nishimuta H, Nakagawa T, Nomura N, Yabuki M. Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. Drug Metab Dispos. 2013;41:1104–11.

    CAS  PubMed  Google Scholar 

  49. Persson B, Heykants J, Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet. 1991;20:263–79.

    CAS  PubMed  Google Scholar 

  50. Mazur CS, Kenneke JF, Goldsmith MR, Brown C. Contrasting influence of NADPH and a NADPH-regenerating system on the metabolism of carbonyl-containing compounds in hepatic microsomes. Drug Metab Dispos. 2009;37:1801–5.

    CAS  PubMed  Google Scholar 

  51. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 2010;53:8441–60.

    CAS  PubMed  Google Scholar 

  52. Jones JP, Korzekwa KR. Predicting intrinsic clearance for drugs and drug candidates metabolized by aldehyde oxidase. Mol Pharm. 2013;10:1262–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229–32.

    CAS  PubMed  Google Scholar 

  54. Miao Z, Kamel A, Prakash C. Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metab Dispos. 2005;33:879–83.

    CAS  PubMed  Google Scholar 

  55. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002;32:835–47.

    CAS  PubMed  Google Scholar 

  56. Zientek M, Jiang Y, Youdim K, Obach RS. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 2010;38:1322–7.

    CAS  PubMed  Google Scholar 

  57. Akabane T, Gerst N, Masters JN, Tamura K. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica. 2012;42:863–71.

    CAS  PubMed  Google Scholar 

  58. Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos. 2010;31:286–97.

    CAS  PubMed  Google Scholar 

  59. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38:215–22.

    CAS  PubMed  Google Scholar 

  60. Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, et al. Comparison of the predictability of human hepatic clearance for organic anion transporting polypeptide substrate drugs between different in vitro-in vivo extrapolation approaches. J Pharm Sci. 2017;106:2678–87.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Preclinical Research Unit, Sumitomo Dainippon Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka, 554-0022, Japan

    Haruka Nishimuta, Takao Watanabe & Kiyoko Bando

Authors
  1. Haruka Nishimuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takao Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiyoko Bando
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haruka Nishimuta.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 212 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishimuta, H., Watanabe, T. & Bando, K. Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes. AAPS J 21, 20 (2019). https://doi.org/10.1208/s12248-019-0294-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-019-0294-1

KEY WORDS

Search

Navigation